Can These Soaring Biotech Stocks Fly Higher?

These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead? Christmas came early this year for anyone holding shares of these three biotech stocks. Each one produced eye-popping gains in 2019, but investors need to know if they can keep climbing in 2020 and beyond. Company Year-to-Date Gain Market Cap…

Why Synthorx Stock Is Soaring Today

Sanofi and the clinical-stage biotech Synthorx announced a $2.5 billion buyout agreement Monday morning. What happened Shares of the clinical-stage biotech Synthorx (NASDAQ:THOR) jumped by an eye-popping 169% right out of the gate Monday morning. What’s behind this enormous spike? Synthorx’s stock is on fire today in response to an all-cash buyout agreement with French…

Is bluebird bio a Buy?

Though the biotech company’s future looks promising, developing successful gene therapies is extraordinarily challenging. Investing in biotech stocks isn’t for the faint of heart. These companies often boast one (or more) potential blockbuster drugs, but a single misstep on the path to approval — such as a negative clinical trial result or a regulatory setback…

Why Aptose Biosciences Shares Jumped Today

Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors. What happened Shares of Aptose Biosciences (NASDAQ:APTO) are up 11.5% as of 3 p.m. EST on Wednesday. This nice gain followed a huge move for the biotech stock on Monday. There were two major catalysts for Aptose. First, the…

Here’s Why bluebird bio Shares Jumped Almost 12% Today

Solid data from the biggest blood disease meeting of the year has the biotech flying high. What happened Shares of bluebird bio (NASDAQ:BLUE) jumped 11.9% today after the biotech presented data from a pair of clinical trials at the American Society of Hematology (ASH) annual meeting. So what Bluebird presented data from the late-stage Northstar-3…

Here’s Why ImmunoGen Jumped 12.4% Today

Investors in the cancer-focused biotech are hoping for good news next week. What happened Shares of ImmunoGen (NASDAQ:IMGN) closed Wednesday 12.4% higher as investors piled into the biotech ahead of the American Society of Hematology (ASH) Annual Meeting, which starts Saturday.http://investor.immunogen.com/news-releases/news-release-details/immunogen-present-new-data-imgn632-61st-ash-annual-meeting So what On Monday afternoon at ASH, ImmuoGen is scheduled to present data from…

3 Top Biotech Stocks to Buy in December

These biotech stocks cover all the bases, from great dividends to promising pipelines. Will biotech stocks have a big year in 2020? I have no idea. But there are three stocks that I expect will deliver great returns over the long run and quite possibly will do so next year. One’s a dividend investor’s dream.…

Here’s Why You Should Own Amgen Stock in 2020

The biotech titan is poised for another strong year in 2020. Biotech posted exceptional gains in 2019. Despite a rocky year on the political front, biotech stocks were able to surge higher this year on the back of several unexpectedly strong top-line data readouts in key therapeutic areas, a number of high-dollar buyouts, and an…